These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 19026643

  • 1. HSP90 is required for TAK1 stability but not for its activation in the pro-inflammatory signaling pathway.
    Liu XY, Seh CC, Cheung PC.
    FEBS Lett; 2008 Dec 10; 582(29):4023-31. PubMed ID: 19026643
    [Abstract] [Full Text] [Related]

  • 2. Heat shock protein 90 (Hsp90) regulates the stability of transforming growth factor beta-activated kinase 1 (TAK1) in interleukin-1beta-induced cell signaling.
    Shi L, Zhang Z, Fang S, Xu J, Liu J, Shen J, Fang F, Luo L, Yin Z.
    Mol Immunol; 2009 Feb 10; 46(4):541-50. PubMed ID: 18950863
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A.
    Clin Cancer Res; 2006 Jan 15; 12(2):584-90. PubMed ID: 16428504
    [Abstract] [Full Text] [Related]

  • 4. Specific regulation of noncanonical p38alpha activation by Hsp90-Cdc37 chaperone complex in cardiomyocyte.
    Ota A, Zhang J, Ping P, Han J, Wang Y.
    Circ Res; 2010 Apr 30; 106(8):1404-12. PubMed ID: 20299663
    [Abstract] [Full Text] [Related]

  • 5. Geldanamycin interferes with the 90-kDa heat shock protein, affecting lipopolysaccharide-mediated interleukin-1 expression and apoptosis within macrophages.
    Hsu HY, Wu HL, Tan SK, Li VP, Wang WT, Hsu J, Cheng CH.
    Mol Pharmacol; 2007 Jan 30; 71(1):344-56. PubMed ID: 16868182
    [Abstract] [Full Text] [Related]

  • 6. Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis.
    Madrigal-Matute J, López-Franco O, Blanco-Colio LM, Muñoz-García B, Ramos-Mozo P, Ortega L, Egido J, Martín-Ventura JL.
    Cardiovasc Res; 2010 May 01; 86(2):330-7. PubMed ID: 20154064
    [Abstract] [Full Text] [Related]

  • 7. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
    Bonvini P, Gastaldi T, Falini B, Rosolen A.
    Cancer Res; 2002 Mar 01; 62(5):1559-66. PubMed ID: 11888936
    [Abstract] [Full Text] [Related]

  • 8. Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors.
    Grover A, Shandilya A, Agrawal V, Pratik P, Bhasme D, Bisaria VS, Sundar D.
    Biochem Biophys Res Commun; 2011 Jan 07; 404(1):498-503. PubMed ID: 21144839
    [Abstract] [Full Text] [Related]

  • 9. Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37.
    Nony P, Gaude H, Rossel M, Fournier L, Rouault JP, Billaud M.
    Oncogene; 2003 Dec 11; 22(57):9165-75. PubMed ID: 14668798
    [Abstract] [Full Text] [Related]

  • 10. The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis.
    Dello Russo C, Polak PE, Mercado PR, Spagnolo A, Sharp A, Murphy P, Kamal A, Burrows FJ, Fritz LC, Feinstein DL.
    J Neurochem; 2006 Dec 11; 99(5):1351-62. PubMed ID: 17064348
    [Abstract] [Full Text] [Related]

  • 11. Stercurensin inhibits nuclear factor-κB-dependent inflammatory signals through attenuation of TAK1-TAB1 complex formation.
    Kim YJ, Kim HC, Ko H, Amor EC, Lee JW, Yang HO.
    J Cell Biochem; 2011 Feb 11; 112(2):548-58. PubMed ID: 21268076
    [Abstract] [Full Text] [Related]

  • 12. Heat shock protein 90 regulates the stability of MEKK3 in HEK293 cells.
    Fang S, Fu J, Yuan X, Han C, Shi L, Xin Y, Luo L, Yin Z.
    Cell Immunol; 2009 Feb 11; 259(1):49-55. PubMed ID: 19560753
    [Abstract] [Full Text] [Related]

  • 13. TAB3, a new binding partner of the protein kinase TAK1.
    Cheung PC, Nebreda AR, Cohen P.
    Biochem J; 2004 Feb 15; 378(Pt 1):27-34. PubMed ID: 14670075
    [Abstract] [Full Text] [Related]

  • 14. Cdk2: a genuine protein kinase client of Hsp90 and Cdc37.
    Prince T, Sun L, Matts RL.
    Biochemistry; 2005 Nov 22; 44(46):15287-95. PubMed ID: 16285732
    [Abstract] [Full Text] [Related]

  • 15. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
    Yu W, Rao Q, Wang M, Tian Z, Lin D, Liu X, Wang J.
    Leuk Res; 2006 May 22; 30(5):575-82. PubMed ID: 16213582
    [Abstract] [Full Text] [Related]

  • 16. The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation.
    Schnaider T, Somogyi J, Csermely P, Szamel M.
    Cell Stress Chaperones; 2000 Jan 22; 5(1):52-61. PubMed ID: 10701840
    [Abstract] [Full Text] [Related]

  • 17. Hsp90/p50cdc37 is required for mixed-lineage kinase (MLK) 3 signaling.
    Zhang H, Wu W, Du Y, Santos SJ, Conrad SE, Watson JT, Grammatikakis N, Gallo KA.
    J Biol Chem; 2004 May 07; 279(19):19457-63. PubMed ID: 15001580
    [Abstract] [Full Text] [Related]

  • 18. L347P PINK1 mutant that fails to bind to Hsp90/Cdc37 chaperones is rapidly degraded in a proteasome-dependent manner.
    Moriwaki Y, Kim YJ, Ido Y, Misawa H, Kawashima K, Endo S, Takahashi R.
    Neurosci Res; 2008 May 07; 61(1):43-8. PubMed ID: 18359116
    [Abstract] [Full Text] [Related]

  • 19. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R, Ohyashiki JH, Kobayashi C, Hamamura R, Zhang Y, Hirano T, Ohyashiki K.
    Cancer Lett; 2009 Oct 18; 284(1):62-70. PubMed ID: 19464103
    [Abstract] [Full Text] [Related]

  • 20. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
    Roforth MM, Tan C.
    Anticancer Drugs; 2008 Aug 18; 19(7):681-8. PubMed ID: 18594209
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.